According to the IMARC Group, the chronic refractory cough market reached a value of US$ 9.4 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 14.1 Billion by 2034, exhibiting a growth rate (CAGR) of 3.74% during 2024-2034. This can be attributed to the emerging popularity of superior laryngeal nerve block as a long-term treatment alternative, owing to its numerous advantages, including high patient compliance, feasibility, safety, and improved quality of life.Chronic refractory cough (CRC) represents a condition in which a person experiences a persistent cough that lasts for more than eight weeks despite undergoing multiple treatments. The chronic refractory cough market is expanding due to its rising prevalence, often linked to underlying conditions, such as asthma, gastroesophageal reflux disease (GERD), and post-viral syndromes, which is driving the need for specialized treatments. Besides this, growing awareness among healthcare providers and patients about CRC as a distinct clinical entity is fostering earlier diagnosis and targeted management, thereby catalyzing the chronic refractory cough market growth. Advancements in pharmacological therapies, particularly P2X3 receptor antagonists, are transforming the treatment landscape by addressing the neural mechanisms underlying the condition.
Notable examples include gefapixant, which has demonstrated promising efficacy in reducing cough frequency and improving patient quality of life. Additionally, non-pharmacological approaches, such as speech therapy and behavioral cough suppression techniques, are being increasingly adopted as complementary interventions, further augmenting the chronic refractory cough market expansion. Government health initiatives and increased funding for respiratory research are accelerating the development of innovative therapies.
Request for a sample of this report: https://www.imarcgroup.com/chronic-refractory-cough-market/requestsample
Countries Covered:
• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
This report also provides a detailed analysis of the current Chronic Refractory Cough Market drugs and late-stage pipeline drugs.
In-Market Drugs:
• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
Late-Stage Pipeline Drugs:
• Drug overview
• Mechanism of action
• Regulatory status
• Clinical trial results
• Drug uptake and market performance
Explore the Full Report with TOC: https://www.imarcgroup.com/chronic-refractory-cough-market
Competitive Landscape with key players:
The competitive landscape of the Chronic Refractory Cough Market has been studied in the report with the detailed profiles of the key players operating in the market.
1. Bellus Health
2. Merck & Co
3. Bayer
4. Shionogi
5. Axalbion
About Us:
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services.
Contact US:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145